Clopidogrel
- Generic Name
- Clopidogrel
- Brand Names
- Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)
- Drug Type
- Small Molecule
- Chemical Formula
- C16H16ClNO2S
- CAS Number
- 113665-84-2
- Unique Ingredient Identifier
- A74586SNO7
- Background
Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,
It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.
Clopidogrel was granted FDA approval on 17 November 1997.
- Indication
1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；
2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；
3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events
- Associated Therapies
- -
Efficacy of DLBS1033 in Patients With Acute Ischemic Stroke
- Conditions
- Interventions
- First Posted Date
- 2013-02-13
- Last Posted Date
- 2014-06-04
- Lead Sponsor
- Dexa Medica Group
- Target Recruit Count
- 126
- Registration Number
- NCT01790997
- Locations
- 🇮🇩
Stroke Unit, Department of Neurology, Faculty of Medicine, Gadjah Mada University, dr. Sardjito Hospital, Yogyakarta, Jogjakarta, Indonesia
Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation
- First Posted Date
- 2013-02-12
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Tufts Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT01789814
- Locations
- 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
Standard Clopidogrel Versus Prasugrel Low Dose Therapy in Elderly Patients With Acute Coronary Syndrome
- First Posted Date
- 2013-01-29
- Last Posted Date
- 2013-01-29
- Lead Sponsor
- Gennaro Sardella
- Target Recruit Count
- 68
- Registration Number
- NCT01778842
- Locations
- 🇮🇹
Dept.of Cardiovascular Sciences,Policlinico Umberto I, Rome, Italy
The Elderly ACS II Trial
- First Posted Date
- 2013-01-29
- Last Posted Date
- 2016-10-21
- Lead Sponsor
- Arcispedale Santa Maria Nuova-IRCCS
- Target Recruit Count
- 2000
- Registration Number
- NCT01777503
- Locations
- 🇮🇹
Azienda Ospedaliera "Ospedale Civile di Legnano", Legnano, MI, Italy
🇮🇹Arcispedale Santa Maria Nuova- IRCCS, Reggio Emilia, Italy
Vasoactive and Anti-inflammatory Effects of Prasugrel in Acute Coronary Syndrome
- Conditions
- Interventions
- First Posted Date
- 2013-01-24
- Last Posted Date
- 2015-06-11
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 49
- Registration Number
- NCT01774838
- Locations
- 🇩🇪
Cardiology, University Hospital of Cologne, Cologne, Germany
Whole Blood Platelet Aggregation in Chronic Kidney Disease Patients on Aspirin Study
- First Posted Date
- 2013-01-15
- Last Posted Date
- 2019-04-19
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 48
- Registration Number
- NCT01768637
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
The Carotid and Middle Cerebral Artery Occlusion Surgery Study
- Conditions
- Interventions
- First Posted Date
- 2013-01-01
- Last Posted Date
- 2021-11-12
- Lead Sponsor
- Xuanwu Hospital, Beijing
- Target Recruit Count
- 330
- Registration Number
- NCT01758614
- Locations
- 🇨🇳
Department of neurosurgery, Xuanwu hospital, Beijing, Beijing, China
Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2012-12-06
- Lead Sponsor
- AHEPA University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT01743014
- Locations
- 🇬🇷
Aristotle University of Thessaloniki/ AHEPA University Hospital, Thessaloniki, Greece
🇬🇷AHEPA University Hospital, Thessaloniki, Greece
Study to See if Platelet Transfusion Stop or Lessen the Effect of the Drug on Platelets
- Conditions
- Interventions
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2014-04-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 258
- Registration Number
- NCT01744288
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Tailored Antiplatelet Therapy Following PCI
- Conditions
- Interventions
- First Posted Date
- 2012-12-05
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 5276
- Registration Number
- NCT01742117
- Locations
- 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸The Feinstein Institute for Medical Research, Manhasset, New York, United States
🇨🇦Humber River Hospital, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.